AU1153902A - Nogo receptor homologs - Google Patents

Nogo receptor homologs

Info

Publication number
AU1153902A
AU1153902A AU1153902A AU1153902A AU1153902A AU 1153902 A AU1153902 A AU 1153902A AU 1153902 A AU1153902 A AU 1153902A AU 1153902 A AU1153902 A AU 1153902A AU 1153902 A AU1153902 A AU 1153902A
Authority
AU
Australia
Prior art keywords
proteins
nogo
methods
compositions
specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1153902A
Other languages
English (en)
Inventor
Stephen M Strittmatter
Richard L Cate
Dinah W Y Sah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biogen Inc
Original Assignee
Yale University
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Biogen Inc filed Critical Yale University
Publication of AU1153902A publication Critical patent/AU1153902A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU1153902A 2000-10-06 2001-10-06 Nogo receptor homologs Pending AU1153902A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23836100P 2000-10-06 2000-10-06
PCT/US2001/031488 WO2002029059A2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Publications (1)

Publication Number Publication Date
AU1153902A true AU1153902A (en) 2002-04-15

Family

ID=22897532

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1153902A Pending AU1153902A (en) 2000-10-06 2001-10-06 Nogo receptor homologs
AU2002211539A Ceased AU2002211539B2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002211539A Ceased AU2002211539B2 (en) 2000-10-06 2001-10-06 Nogo receptor homologs

Country Status (12)

Country Link
US (5) US20030124704A1 (enExample)
EP (1) EP1325130B1 (enExample)
JP (2) JP4465148B2 (enExample)
AT (1) ATE458815T1 (enExample)
AU (2) AU1153902A (enExample)
CA (1) CA2424834A1 (enExample)
DE (1) DE60141409D1 (enExample)
DK (1) DK1325130T3 (enExample)
ES (1) ES2341608T3 (enExample)
NZ (1) NZ525422A (enExample)
PT (1) PT1325130E (enExample)
WO (1) WO2002029059A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
WO2003018631A2 (en) * 2001-08-27 2003-03-06 Novartis Ag Nogo receptor homologues and their use
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
AU2003246254A1 (en) * 2002-07-05 2004-01-23 Shionogi And Co., Ltd. NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF
CA2495121A1 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists
EP2902491A1 (en) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO receptor binding protein
EP1623036A4 (en) * 2003-04-04 2007-06-20 Univ Rochester IDENTIFICATION OF NEW NOGO RECEPTORS AND ASSOCIATED METHODS
MXPA05011100A (es) * 2003-04-16 2006-04-18 Univ Yale Antagonistas de receptor nogo para el tratamiento de condiciones que comprenden placas amiloideas.
EA008253B1 (ru) * 2003-08-07 2007-04-27 Байоджен Айдек Ма Инк. Антагонисты nogo-рецептора
EP1695061A4 (en) * 2003-12-16 2008-02-20 Childrens Medical Center METHOD OF TREATING NEUROLOGICAL DISORDERS
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
CN1946418A (zh) * 2004-01-30 2007-04-11 比奥根艾迪克Ma公司 利用nogo受体拮抗剂治疗涉及多巴胺能神经元退变的疾病
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
JP2008515804A (ja) * 2004-10-01 2008-05-15 イェール ユニバーシティ Ｎｏｇｏ−Ａポリペプチド断片、改変体Ｎｏｇｏレセプター１ポリペプチドおよびそれらの使用
EP1904091A4 (en) * 2005-07-07 2009-12-23 Univ Yale COMPOSITIONS AND METHODS FOR SUPPRESSING THE INHIBITION OF AXON GROWTH
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
JP2009505665A (ja) * 2005-08-25 2009-02-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｎｏｇｏ受容体ポリペプチドおよびポリペプチドフラグメント、ならびにそれらの使用
JP5829373B2 (ja) 2006-01-27 2015-12-09 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｎｏｇｏレセプターアンタゴニスト
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
WO2007137303A2 (en) * 2006-05-24 2007-11-29 Myelin Repair Foundation, Inc. Permeability of blood-brain barrier
US20100047232A1 (en) * 2006-11-14 2010-02-25 Jasvinder Atwal Modulators of neuronal regeneration
AU2007319359A1 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
CN101971034A (zh) * 2007-12-11 2011-02-09 健泰科生物技术公司 神经元再生的调控剂
US8992918B2 (en) 2008-03-13 2015-03-31 Yale University Reactivation of axon growth and recovery in chronic spinal cord injury
CL2009001155A1 (es) * 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2392208B1 (en) * 2010-06-07 2016-05-04 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease and their use
US9120111B2 (en) 2012-02-24 2015-09-01 Rain Bird Corporation Arc adjustable rotary sprinkler having full-circle operation and automatic matched precipitation
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
US9156043B2 (en) 2012-07-13 2015-10-13 Rain Bird Corporation Arc adjustable rotary sprinkler with automatic matched precipitation
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
US12343748B2 (en) 2021-03-16 2025-07-01 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method
US12434252B2 (en) 2022-04-20 2025-10-07 Rain Bird Corporation Full-circle and part-circle rotor sprinkler
US12440855B2 (en) 2022-10-27 2025-10-14 Rain Bird Corporation Multi-mode rotor sprinkler apparatus and method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
AU652537B2 (en) 1988-11-04 1994-09-01 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
CA2117889A1 (en) 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO1999007891A1 (en) * 1997-08-05 1999-02-18 Human Genome Sciences, Inc. 90 human secreted proteins
WO2000070050A1 (en) 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1490386B1 (en) 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
JP2002518010A (ja) * 1998-06-16 2002-06-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９４個のヒト分泌タンパク質
EP2264174A3 (en) 1998-07-22 2012-03-07 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding CDNA
KR100728405B1 (ko) * 1998-11-06 2007-06-13 더 유니버시티 오브 취리히 Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
EP1135485B1 (en) 1998-12-01 2010-02-17 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20030002292A (ko) 1999-03-08 2003-01-08 제넨테크, 인크. 분비 및 막횡단 폴리펩티드 및 이를 코딩하는 핵산
EP1165784A2 (en) 1999-03-31 2002-01-02 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
AU6394400A (en) 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
AU2575901A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel leucine rich repeat-containing molecules and uses therefor
ES2341842T3 (es) * 2000-01-12 2010-06-29 Yale University Bloqueo del crecimiento axonal mediado por el receptor de nogo.
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6695956B2 (en) 2000-04-18 2004-02-24 Teijin Limited Oxygen concentrating apparatus
ES2341608T3 (es) * 2000-10-06 2010-06-23 Yale University Homologos del receptor de nogo.
WO2003018631A2 (en) 2001-08-27 2003-03-06 Novartis Ag Nogo receptor homologues and their use
JP2005519584A (ja) * 2001-10-22 2005-07-07 ノバルティス アクチエンゲゼルシャフト Ｎｏｇｏレセプターホモログおよびそれらの使用
CA2495121A1 (en) * 2002-08-10 2004-02-19 Yale University Nogo receptor antagonists

Also Published As

Publication number Publication date
EP1325130B1 (en) 2010-02-24
JP2004528809A (ja) 2004-09-24
US20030124704A1 (en) 2003-07-03
US7173118B2 (en) 2007-02-06
US20090175850A1 (en) 2009-07-09
EP1325130A2 (en) 2003-07-09
WO2002029059A9 (en) 2003-05-15
US20050048520A1 (en) 2005-03-03
NZ525422A (en) 2006-09-29
ATE458815T1 (de) 2010-03-15
US20070104713A1 (en) 2007-05-10
PT1325130E (pt) 2010-05-31
AU2002211539B2 (en) 2007-01-25
ES2341608T3 (es) 2010-06-23
WO2002029059A2 (en) 2002-04-11
WO2002029059A3 (en) 2003-01-23
DE60141409D1 (de) 2010-04-08
CA2424834A1 (en) 2002-04-11
JP2009100767A (ja) 2009-05-14
DK1325130T3 (da) 2010-05-25
JP4465148B2 (ja) 2010-05-19
US20110129477A1 (en) 2011-06-02
US7456255B2 (en) 2008-11-25

Similar Documents

Publication Publication Date Title
AU1153902A (en) Nogo receptor homologs
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
DE60028970D1 (de) An her2 bindende peptidverbindungen
BR0306973A (pt) Anticorpos anti-igf-ir e respectivas aplicações
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2004019893A3 (en) Modulators of angiogenesis
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
WO2010065536A3 (en) Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
DK0811068T3 (da) Humane DNase I varianter
DE50015355D1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide
MXPA03005564A (es) Nueva proteina que contiene repeticiones ricas en leucina de humano que es expresada predominantemente en medula osea, hlrrbm1.
TW200635953A (en) Specific binding agents of human angiopoietin-2
WO2002046380A3 (en) Protein kinase